# Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects

> **NCT07200986** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Celltrion** · enrollment: 218 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** Ixekizumab

## Key facts

- **NCT ID:** NCT07200986
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-17
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07200986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07200986, "Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07200986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*